It could also be pretty awesome if there was a labeling requirement on all FDA approved drugs for effect size, from a red "not very effective" to a yellow "moderately effective" to green "highly effective".
I think you miss the point of the parent post. The point would be to allow drug companies to sell drugs that are reasonably safe, but efficacy is unknown. This would allow drugs and products to come to patients quicker, in a way that is decoupled from reimbursement.
>It could also be pretty awesome if there was a labeling requirement on all FDA approved drugs for effect size, from a red "not very effective" to a yellow "moderately effective" to green "highly effective".
You are in luck! The FDA has what are literally called "Labeling Requirements" for all approved drugs, which includes a description effect sizes and side effects. You can find the effect sizes by searching "Prescribing information [Drug Name]". It doesn't include a color code, but does have "X% of patients had Y effect, Z% of patients had N effect, ect"
1) Timing: There are people who suffer and die while products are held up in lengthy phase 3 approvals. 2) Human Impact: There are drugs& devices which are safe, but have weak efficacy data. For some like aducanumab, if they work, they could help millions of people today. This puts the FDA in a tough spot weighing a big potential benefit to society against things medicare costs for a low/no efficacy drug.
Im personally not advocating for throwing open the gates to any snake oil. I think a reasonable proposal would be to require robust data on safety, a strong argument for why it should work, and require monitoring of efficacy after approval.
If time tells that your magic pills dont work, they get pulled from the market. If time tells that they do work, you get your gold star
The first link in this post explains it better than I can.
Although in practice I guess this would probably not be very different from 'not approved', in which case it seems right for the FDA to reject ineffective drugs.
In any case, one thing we definitely do not want is to incentivize the creation of ineffective drugs, especially expensive ones.